Ionis Pharma's Investigational Drug Shows Promise For Triglyceride And Pancreatitis Reduction

Medical,,Research,And,Scientist,In,Laboratory,With,Microscope,,Observation,And

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) on Tuesday released topline results from the pivotal Phase 3 CORE and CORE2 studies of olezarsen for severe hypertriglyceridemia (sHTG).

sHTG is a condition where triglyceride levels are significantly elevated, typically 500 mg/dL or higher, which is a major risk factor for acute pancreatitis.